IPCA LABORATORIES LTD Q1 RESULTS
A Trump tariff tantrum-proof sector? 8 stocks from pharma sector, where Democrats and Republicans are in agreement, with an upside potential of up to 34% in 1 year
When Donald Trump is back in the saddle, one thing is certain: Tariff wars. Yes, China will be the biggest target. But for all those who think India will be unaffected, just do a Google search for “Trump on high import duty on Harley Davidson bikes”. A further indication came just a few days ago when he mentioned Brazil and India in the same breath, saying that the two countries were imposing high tariffs and should expect consequences. While it may not become a major issue, there may well be some retaliation. Or the threat of retaliation could be used as a tool to get India to change its stance on some global issue. Or as a quid pro quo: For instance, a push for lower duties on EVs, especially cars – a move that could help Trump’s biggest backer Elon Musk and his Tesla. But one sector which would be relatively safe could be pharma, and there are reasons for it. And mind you, we are using the word “relatively”.
SBI, Tata Motors among Motilal Oswal's top winners & losers post a dull Q2 earnings season
Motilal Oswal Financial Services highlighted both winners and laggards in a subdued Q2 for corporate India. SBI and L&T led the gainers, demonstrating resilience and growth, while Tata Motors and Asian Paints faced challenges. Nifty-50 earnings saw modest growth, prompting Motilal Oswal to lower FY25 EPS estimates but anticipate a 2HFY25 recovery driven by increased consumer and government spending.
InCred cuts Nifty50 blended index target to 25,327, upgrades pharma to overweight
InCred Equities cut Nifty50 target to 25,327, expecting a correction phase. The brokerage upgraded its stance on pharma stocks like Cipla, Ipca, and Alkem Laboratories. The IT, capital goods, and pharma sectors outperformed during the recent correction. The overall market sentiment remains cautious due to weak macroeconomic conditions and potential EPS downgrades.
As smog engulfs the street, essential pills for a healthy of portfolio: 5 pharma stocks with an upside potential of up to 39%
Here’s a lesson from history: For a long-term investor, buying in a correcting market is mostly an opportunity. The operative part, of course, is “long-term investor” – not people who check the value of their portfolio every evening. Also, focus on a sector that is making a comeback. Why? Because when a sector catches the limelight for the first time, valuations are high – and promoters tend to be more optimistic than realistic. In a sector that has gone through a troubled phase and is making a comeback, promoters have learnt their lessons and are more realistic in their expectations – as also in capital allocation. Pharma is one such sector. And there are more reasons to take a closer look at it.
Ipca Labs Q2 Results: Profit shoots up 58% to Rs 229 crore
Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period.
Alkem Labs Q2 Results: Net profit rises 11% to Rs 689 crore
Alkem Laboratories on Wednesday posted a 11% year-on-year (y-o-y) jump in net profit to Rs 689 crore in Q2FY25 led by growth in domestic formulation sales.
- Go To Page 1
Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25
Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis business. This growth was driven by increased demand from new and existing customers seeking supply chain diversification beyond China.
Divi's Laboratories Q2 Results: PAT jumps 46% YoY to Rs 510 crore on forex gain
Divi's Laboratories Q2 Results: The company reported a 22.5% year-on-year revenue increase in Q2, reaching Rs 2,338 crore, up from Rs 1,909 crore in the previous year’s corresponding quarter. Profit before tax rose to Rs 722 crore, compared to Rs 469 crore in the same period last year.
Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%
Dr Reddy's Labs Q2 Results: Healthcare major Dr Reddy's on Tuesday reported 15% drop in its consolidated net profit at Rs 1255 crore in the second quarter. It was Rs 1480 crore in the year-ago quarter.
Dr. Reddy’s shares trade ex-split today. Stock up 2%
The company further announced that each American Depositary Share (ADS) will continue to represent one equity share. Consequently, the number of ADSs held by each American Depositary Receipt holder will increase in line with the rise in equity shares.
Big chase for a cancer drug: The urgent need for affordable Keytruda alternatives
Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, Indian companies are developing more affordable versions. Efforts are also focused on expanding indications and improving financial access.
Ahead of Market: 10 things that will decide stock action on Thursday
Indian equity indices fell for a third session due to lackluster corporate earnings and foreign selling, despite gains from Bajaj Finance. Analysts suggest Nifty's crucial support is at 24,378; a break below could lead to further declines.
Ipca Labs expects its US generics sales to touch $200 million soon
Ipca Laboratories, after resolving regulatory hurdles and integrating Unichem, is set to re-enter the US generics market aiming for $200 million in revenue within 12-18 months. The focus is on commercializing existing products after an import ban by the US FDA was lifted. Unichem has shown profits following these efforts.
Reduce Ipca Labs, target price Rs 1,250: Prabhudas Lilladher
Ipca Labs (IPCA) Q1 EBITDA of Rs 3.9 bn was in line with our estimate. Management guidance of 9% revenue growth (excluding Unichem) was below our estimate while increase margin guidance by 50-110 bps.
Ipca Labs Q1 Results: Net profit up 18% at Rs 192 crore
Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing.
Q1 results today: Hindalco, Nykaa among 660 companies to announce earnings on Tuesday
Q1 results today: Samvardhana Motherson, Muthoot Finance, SJVN, Max Financial Services, Gujarat Fluorochemicals, Endurance Technologies, Ipca Labs, NBCC (India), Godrej Industries among others will also declare their quarterly results
Q1 results this week: HAL, Ola Electric, Vodafone Idea, IRFC, and Nykaa among 85 companies to announce quarterly earnings
Several widely followed companies, including Vodafone Idea, Hindustan Aeronautics (HAL), Mazagon Dock, Hero MotoCorp, IRFC, IRCTC, HUDCO, Apollo Hospitals, Samvardhana Motherson, GMR Airports Infrastructure, Nykaa, and Ola Electric will be releasing their June quarter report cards this week. Here’s the list:
Alkem Labs Q1 Results: Net profit zooms 90% to Rs 545 crore
The company reported Rs 287 crore in the corresponding quarter of the previous year. Revenue from operations grew 2.2% y-o-y to Rs 3032 crore in Q1FY25.
Q1 results this week: LIC, Airtel, Vedanta, Eicher Motors, Tata Power and others
Power Finance Corp, Vedanta, Tata Power, Britannia Industries, TVS Motor, Bosch, Shree Cement, Solar Industries, Lupin, Linde India, PB Fintech, PI Industries, Berger Paints, Gujarat Gas, and others will announce their June quarter results.
Q1 results, IPO action among 10 factors that will steer D-Street this week
The Street will react to major earnings reports from SBI, Divi’s Laboratories, Titan, and Britannia when markets resume trading on Monday. Additionally, 922 BSE-listed companies will announce April-June earnings, including Bharti Airtel and Tata Power. Indian markets will take cues from US market closures and GIFT Nifty futures.
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%
Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio of 1:5, which means that 1 existing share will split into 5. The company said its revenue growth during the quarter was largely driven by growth in global generics revenues in North America as well as India.
Thyrocare Technologies shares soar nearly 17% as Q1 results impress D-Street
Thyrocare’s pathology and radiology segments’ revenues grew 16% and 15% YoY, respectively. Meanwhile the revenue from partnerships surged 29% YoY and franchise revenue saw an increase of 11% YoY.
Q4 results: Stable costs boost India Inc. profits
Steady costs and firm domestic demand supported corporate performance in the March quarter.
Divi’s Laboratories shares rally 5% post Q4 results. Should you buy, sell or hold?
Divi’s Laboratories saw a 5% surge in its shares on the BSE during Monday's trading session, reaching a new 52-week high of Rs 4,335. This rise came as brokerages such as Motilal Oswal and InCred expressed bullish sentiment towards the stock, following the company's impressive performance in Q4, where it reported a 68% year-on-year increase in profits, reaching Rs 538 crore.
Divi's Laboratories Q4 Results: Cons PAT soars 68% YoY to Rs 538 crore; dividend declared at Rs 30 per share
Divi's Laboratories Q4 Results: Net profit stood at Rs 321 crore in the corresponding quarter of the last financial year. The consolidated revenue in Q4 FY24 jumped 18% YoY to Rs 2,303 crore from Rs 1,951 crore reported in Q4 FY23. For the full financial year FY24, the consolidated profit after tax was reported at Rs 1,600 crore, a considerable drop from Rs 1,824 crore reported in FY23.
Dr Lal PathLabs Q4 Results: Net profit rises 51% YoY to Rs 86 crore on improved volumes of diagnostic tests
Dr Lal PathLabs on Friday reported a 51% year-on-year (YoY) jump in net profit to Rs 86 crore in the quarter ended March 2024 led by improved volumes of diagnostic tests.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Preview: PAT may rise over 50% YoY on strong US sales
Based on an average estimate from four brokerages, revenue from operations during the January-March 2023 period is anticipated to increase by up to 18% year-on-year. Concurrently, the net profit after tax is expected to experience a robust surge of up to 54% year-on-year.
Load More
